BioNTech SE ADR (NASDAQ: BNTX)’s stock price has decreased by -1.42 compared to its previous closing price of 119.58. However, the company has seen a 5.35% increase in its stock price over the last five trading sessions. zacks.com reported 2025-02-13 that BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is It Worth Investing in BioNTech SE ADR (NASDAQ: BNTX) Right Now?
The 36-month beta value for BNTX is at 0.28. Analysts have varying views on the stock, with 12 analysts rating it as a “buy,” 4 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BNTX is 235.99M, and currently, shorts hold a 1.16% of that float. The average trading volume for BNTX on February 21, 2025 was 718.26K shares.
BNTX’s Market Performance
The stock of BioNTech SE ADR (BNTX) has seen a 5.35% increase in the past week, with a 0.54% rise in the past month, and a 18.21% gain in the past quarter. The volatility ratio for the week is 4.67%, and the volatility levels for the past 30 days are at 4.36% for BNTX. The simple moving average for the past 20 days is -1.42% for BNTX’s stock, with a 13.73% simple moving average for the past 200 days.
Analysts’ Opinion of BNTX
Many brokerage firms have already submitted their reports for BNTX stocks, with Truist repeating the rating for BNTX by listing it as a “Buy.” The predicted price for BNTX in the upcoming period, according to Truist is $172 based on the research report published on January 10, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $170. The rating they have provided for BNTX stocks is “Overweight” according to the report published on December 11th, 2024.
BNTX Trading at 0.22% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.35% of loss for the given period.
Volatility was left at 4.36%, however, over the last 30 days, the volatility rate increased by 4.67%, as shares surge +2.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.81% lower at present.
During the last 5 trading sessions, BNTX rose by +5.35%, which changed the moving average for the period of 200-days by +27.80% in comparison to the 20-day moving average, which settled at $119.57. In addition, BioNTech SE ADR saw 3.45% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNTX starting from Medine GmbH, who proposed sale 1,000,000 shares at the price of $119.58 back on Feb 20 ’25. After this action, Medine GmbH now owns shares of BioNTech SE ADR, valued at $119,580,000 using the latest closing price.
Poetting Sierk, the Officer of BioNTech SE ADR, proposed sale 120,000 shares at $119.58 during a trade that took place back on Feb 20 ’25, which means that Poetting Sierk is holding shares at $14,349,600 based on the most recent closing price.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.84 for the gross margin
The net margin for BioNTech SE ADR stands at -0.16. The total capital return value is set at -0.03. Equity return is now at value -2.37, with -2.07 for asset returns.
Based on BioNTech SE ADR (BNTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 6.39. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17.5.
Currently, EBITDA for the company is 1.09 billion with net debt to EBITDA at 104.32. When we switch over and look at the enterprise to sales, we see a ratio of 5.67. The receivables turnover for the company is 2.52for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.33.
Conclusion
In conclusion, BioNTech SE ADR (BNTX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
